Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer. (Selebrec)

N

National Cancer Institute, Naples

Status

Enrolling

Conditions

Breast Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT05817227
57/21oss (Other Identifier)
SELEBREC

Details and patient eligibility

About

This is multicentric, spontaneous, observational, retrospective and prospective study.

Full description

In the retrospective part of the study, Tissue Microarrays (TMA) will be prepared from surgical samples of breast tissue from a series of patients with TNBC type breast cancer. In the prospective part of the study will be evaluated the expression of some selenoproteins by ELISA in plasma samples obtained from up to 100 healthy subjects and about 300 (~100 per year) patients with basally metastatic TNBC breast cancer (150) and metastatic (150) before any treatment.

Enrollment

300 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • TNBC breast cancer patients, before any drug treatment
  • healthy women aged 25-60

Exclusion criteria

donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.

Trial contacts and locations

0

Loading...

Central trial contact

Susan Costantini, PhD; Elena Di Gennaro, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems